Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1990 Jul;62(1):17–22. doi: 10.1038/bjc.1990.221

1,2-dithiol-3-thione and dithioester analogues: potential radioprotectors.

B A Teicher 1, J Stemwedel 1, T S Herman 1, P K Ghoshal 1, A Rosowsky 1
PMCID: PMC1971736  PMID: 2390477

Abstract

Several 1,2-dithiol-3-thione and dithioester compounds were assayed for radioprotective capabilities in EMT6 cells in vitro. The 1,2-dithiol-3-thiones were generally more cytotoxic than the dithioesters and in some instances were more cytotoxic toward hypoxic cells than toward normally oxygenated cells. When the drugs were present at a concentration of 500 microM for 1 h prior to and during radiation delivery, the 5-(2-thienyl)-1,2-dithiol-3-thione produced a radiation protection factor (RPF) of 2.7 at 1 log of cell kill. The 4-methyl analogue of this same compound was, however, much less effective, producing a RPF of only 1.2. The 4-ethoxycarbonyl analogue was moderately active, producing a RPF of 1.7. The 4-methyl-5-(2-pyrazinyl)-1,2-dithiol-3-thione (Oltipraz) was least effective, yielding a RPF of only 1.1. Of the dithioesters tested, methyl 3-pyrrolidino-2-phenylpropene dithiocarboxylate produced a RPF of 2.6, methyl 3-piperidino-2-phenylpropenedithiocarboxylate a RPF of 2.7, and the corresponding 3-morpholino and 3-thiomorpholino derivatives RPF values of 2.7 and 2.9, respectively. The iodide salt of 4-ethoxycarbonyl-5-(2-thienyl)-1,2-dithiol-3-thione produced a RPF of 2.6 Methyl 3-cyclohexylamino-2-phenylpropenedithiocarboxylate was equally effective (RPF = 2.6). Finally, methyl 3-morpholino-3-thienyl-2-methylpropenedithiocarboxylate and methyl 3-morpholino-3-(2-pyrazinyl)-2-methylpropenedithiocarboxylate were less effective, producing RPF values of 2.0 and 1.6, respectively. These results demonstrate that several of these compounds are highly effective radioprotectors. In vitro and in vivo studies testing their efficacy are underway.

Full text

PDF
17

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ansher S. S., Dolan P., Bueding E. Biochemical effects of dithiolthiones. Food Chem Toxicol. 1986 May;24(5):405–415. doi: 10.1016/0278-6915(86)90205-x. [DOI] [PubMed] [Google Scholar]
  2. Archer S. The chemotherapy of schistosomiasis. Annu Rev Pharmacol Toxicol. 1985;25:485–508. doi: 10.1146/annurev.pa.25.040185.002413. [DOI] [PubMed] [Google Scholar]
  3. Bueding E., Dolan P., Leroy J. P. The antischistosomal activity of oltipraz. Res Commun Chem Pathol Pharmacol. 1982 Aug;37(2):293–303. [PubMed] [Google Scholar]
  4. Constine L. S., Zagars G., Rubin P., Kligerman M. Protection by WR-2721 of human bone marrow function following irradiation. Int J Radiat Oncol Biol Phys. 1986 Aug;12(8):1505–1508. doi: 10.1016/0360-3016(86)90204-x. [DOI] [PubMed] [Google Scholar]
  5. Davies M. H., Blacker A. M., Schnell R. C. Dithiolthione-induced alterations in hepatic glutathione and related enzymes in male mice. Biochem Pharmacol. 1987 Feb 15;36(4):568–570. doi: 10.1016/0006-2952(87)90370-4. [DOI] [PubMed] [Google Scholar]
  6. De Long M. J., Dolan P., Santamaria A. B., Bueding E. 1,2-Dithiol-3-thione analogs: effects on NAD(P)H:quinone reductase and glutathione levels in murine hepatoma cells. Carcinogenesis. 1986 Jun;7(6):977–980. doi: 10.1093/carcin/7.6.977. [DOI] [PubMed] [Google Scholar]
  7. Foye W. O., Jones R. W., Ghoshal P. K. Antiradiation compounds. XXII. Methyl 3-amino-2-phenyldithiopropenoates and 1,1-bis(methylthio)-3-amino-2-phenyl-1-propenes. J Pharm Sci. 1987 Oct;76(10):809–812. doi: 10.1002/jps.2600761012. [DOI] [PubMed] [Google Scholar]
  8. Glover D., Grabelsky S., Fox K., Weiler C., Cannon L., Glick J. Clinical trials of WR-2721 and cis-platinum. Int J Radiat Oncol Biol Phys. 1989 May;16(5):1201–1204. doi: 10.1016/0360-3016(89)90283-6. [DOI] [PubMed] [Google Scholar]
  9. Häusler R., Ritschard J. Utilisation d'un sialagogue (sulfarlem S 25 = TTPT) dans le traitement de la xérostomie. Schweiz Rundsch Med Prax. 1979 Aug 14;68(33):1063–1068. [PubMed] [Google Scholar]
  10. Kensler T. W., Egner P. A., Dolan P. M., Groopman J. D., Roebuck B. D. Mechanism of protection against aflatoxin tumorigenicity in rats fed 5-(2-pyrazinyl)-4-methyl-1,2-dithiol-3-thione (oltipraz) and related 1,2-dithiol-3-thiones and 1,2-dithiol-3-ones. Cancer Res. 1987 Aug 15;47(16):4271–4277. [PubMed] [Google Scholar]
  11. Rockwell S. C., Kallman R. F., Fajardo L. F. Characteristics of a serially transplanted mouse mammary tumor and its tissue-culture-adapted derivative. J Natl Cancer Inst. 1972 Sep;49(3):735–749. [PubMed] [Google Scholar]
  12. Rockwell S., Kallman R. F. Cellular radiosensitivity and tumor radiation response in the EMT6 tumor cell system. Radiat Res. 1973 Feb;53(2):281–294. [PubMed] [Google Scholar]
  13. Teicher B. A., Crawford J. M., Holden S. A., Lin Y., Cathcart K. N., Luchette C. A., Flatow J. Glutathione monoethyl ester can selectively protect liver from high dose BCNU or cyclophosphamide. Cancer. 1988 Oct 1;62(7):1275–1281. doi: 10.1002/1097-0142(19881001)62:7<1275::aid-cncr2820620705>3.0.co;2-i. [DOI] [PubMed] [Google Scholar]
  14. Teicher B. A., Holden S. A. Antitumor and radiosensitizing activity of several platinum-(+) dye complexes. Radiat Res. 1987 Jan;109(1):58–67. [PubMed] [Google Scholar]
  15. Teicher B. A., Lazo J. S., Sartorelli A. C. Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells. Cancer Res. 1981 Jan;41(1):73–81. [PubMed] [Google Scholar]
  16. Teicher B. A., Rockwell S., Lee J. B. Radiosensitization of EMT6 cells by four platinum complexes. Int J Radiat Oncol Biol Phys. 1985 May;11(5):937–941. doi: 10.1016/0360-3016(85)90116-6. [DOI] [PubMed] [Google Scholar]
  17. Wattenberg L. W., Bueding E. Inhibitory effects of 5-(2-pyrazinyl)-4-methyl-1,2-dithiol-3-thione (Oltipraz) on carcinogenesis induced by benzo[a]pyrene, diethylnitrosamine and uracil mustard. Carcinogenesis. 1986 Aug;7(8):1379–1381. doi: 10.1093/carcin/7.8.1379. [DOI] [PubMed] [Google Scholar]
  18. Yuhas J. M., Davis M. E., Glover D., Brown D. Q., Ritter M. Circumvention of the tumor membrane barrier to WR-2721 absorption by reduction of drug hydrophilicity. Int J Radiat Oncol Biol Phys. 1982 Mar-Apr;8(3-4):519–522. doi: 10.1016/0360-3016(82)90674-5. [DOI] [PubMed] [Google Scholar]
  19. Yuhas J. M., Storer J. B. Differential chemoprotection of normal and malignant tissues. J Natl Cancer Inst. 1969 Feb;42(2):331–335. [PubMed] [Google Scholar]
  20. Yuhas J. M., Yurconic M., Kligerman M. M., West G., Peterson D. F. Combined use of radioprotective and radiosensitizing drugs in experimental radiotherapy. Radiat Res. 1977 May;70(2):433–443. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES